1-2 of 2
Brittany Hobbie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Jia Ruan, David A. Bond, Bijal D Shah, John N. Allan, Sarah C. Rutherford, Caitlin Gribbin, Zhengming Chen, Brittany Hobbie, Melinda Harbhajan, Tejasvi Sahni, Wayne Tam, Bhavneet Bhinder, Michael Sigouros, Giorgio Inghirami, Selina Chen-Kiang, Olivier Elemento, Kami J. Maddocks, John P. Leonard, Peter Martin
Journal: Blood
Blood (2024) 144 (Supplement 1): 746.
https://doi.org/10.1182/blood-2024-204495
Published: 2024
Journal Articles

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Jia Ruan, John P. Leonard, Gui Zhen Chen, Zhengming Chen, John N. Allan, Sarah C. Rutherford, Brittany Hobbie, Katie Greig, Amelyn Rodriguez, Wayne Tam, David A. Bond, Bijal D. Shah, Kami J. Maddocks, Bhavneet Binder, Giorgio Inghirami, Olivier Elemento, Selina Chen-Kiang, Peter Martin
Journal: Blood
Blood (2022) 140 (Supplement 1): 175–177.
https://doi.org/10.1182/blood-2022-158656
Published: 2022